Active Surveillance for Localized Prostate Cancer

Cancer Overdiagnosis and Overtreatment. - Can We Screen and Still Reduce Overdiagnosis? . - The Role of Fear in Overdiagnosis and Overtreatment. - Ethical and Legal Considerations in Active Surveillance for Prostate Cancer. - Gleason 6 Tumors Should Still Be Labeled As Cancer. - Risk Based Selection for Active Surveillance. - Surveillance at the Margins: Management of High Volume Gleason 6, PSA > 10, or Gleason 3+4. - How Should Patients on Active Surveillance be Followed? . - Triggers for Intervention. - MR Imaging in Prostate Tumor Volume Assessment: How Accurate? . - Can MRI Replace Biopsy in Men on Surveillance? . - Tissue Based Markers for Risk Prediction. - International AS Registry: The Movember Foundation s Global Action Plan Prostate Cancer Active Surveillance Initiative. - Better Informed Decision Making to Optimize Patient Selection. - How Does QOL Compare Between Surveillance and Active Treatment? . - The Potential Benefits of Diet and Physical Activity among Active Surveillance Patients with Low-Burden Prostate Cancer. - Is there a Role for Pharmacologic Manipulation to Prevent Progression in Men on Active Surveillance? The Role of 5-ARIs, Statins, and Metformin. - The Update of Active Surveillance around the World: Utilization and Outcomes. - Tissue Preservation Active Surveillance and Focal Therapy as Complimentary Strategies. - The Economics of Active Surveillance for Prostate Cancer. - Research Questions in Active Surveillance.